Associations between classic psychedelics and nicotine dependence in a nationally representative sample

This study (2022) draws on a sample of adult participants (n=214,505) in the National Survey on Drug Use and Health to assess whether lifetime classic psychedelic use is associated with lower odds of nicotine dependence. Lifetime use of psilocybin, peyote and mescaline were all associated with reduced odds of nicotine dependence.


“Tobacco use is the single largest cause of preventable death worldwide, but none of the established treatments aimed at smoking cessation work for a majority of smokers. As such, there is an urgent need for interventions capable of reliably treating nicotine addiction. The use of classic psychedelics has been associated with lower odds of many forms of substance dependence. Here we tested whether lifetime use of classic psychedelics (tryptamine, lysergamide, and phenethylamine) is associated with lower odds of current nicotine dependence. We tested these associations in a sample of 214,505 adult participants in the National Survey on Drug Use and Health (2015–2019) using multivariable logistic regression models. Lifetime psilocybin use was associated with reduced odds of current nicotine dependence (aOR 0.87–0.93). Lifetime use of peyote and mescaline also conferred reduced odds of multiple subdomains of a main nicotine dependence measure (Nicotine Dependence Syndrome Scale [NDSS]) (aOR 0.79–0.91). Conversely, lifetime use of LSD was associated with increased odds of nicotine dependence (aOR 1.17–1.24). Psilocybin, mescaline, and peyote use are associated with lowered odds of nicotine dependence. Experimental studies are needed to establish whether these associations are causal. These results make the case for further research into the efficacy of both tryptamine and phenethylamine psychedelics in promoting smoking cessation.”

Authors: Grant Jones, Joshua Lipson & Matthew K. Nock

Become a psychedelic insider!

With a free Blossom membership you will always be in the know.

📰 Weekly newsletter about the psychedelic research

✔️ Unlimited access to our database and original articles

🖊️ Add (private) notes and comments to each page

Make an account

Study details

Compounds studied
Psilocybin Mescaline

Topics studied
Addiction Smoking

Study characteristics

214505 Humans


Institutes associated with this publication

Harvard University
Harvard is working with Mass General and their team at the Center for the Neuroscience of Psychedelics. Harvard Law School recently launched their POPLAR initiative.

Columbia University
This company doesn't have a full profile yet, it is linked to a clinical trial.

Inline Feedbacks
View all comments